The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in ...

Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.